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INTRODUCTION
Patients with severe hemophilia A lack clotting factor VIII. As a consequence, they suffer from recurrent spontaneous and trauma related bleeds. The majority of these bleeds are located in the joints, ultimately resulting in hemophilic arthropathy. Severe arthropathy is associated with chronic pain, joint destruction, and disability. Since the introduction of replacement therapy (1) , treatment has continuously been intensified. Moreover, treatment per bleeding episode has shifted towards regular prophylactic infusions to prevent bleeds, especially in children (2) (3) (4) . Both in the Netherlands and Sweden, prophylaxis has been standard treatment for over 30 years. In general, more intensive treatment is associated with better outcome. However, the use of clotting factor is associated with high costs and this may be one of the main factors why prophylaxis is not adopted as standard treatment in all Western countries (5) . For example, the annual consumption for a young adult on prophylaxis in the Netherlands would be 105,000 IU (6) . In Sweden, higher dosages are used, and the average consumption would be 280,000 IU/yr (2) . However, on demand treatment may lead to more varied clotting factor consumption and mean consumptions as high as 140,000 IU/yr per patient have been reported (7;8) .
Given the high costs of this life-long treatment, it is important to use clotting factor concentrates in the most efficient manner by balancing consumption and effects. This balance may differ per patient and vary in different stages of life. Assessing life-long consumption and effects requires evaluation of all different strategies used.
Unfortunately, studies on long-term effects of different treatment strategies for severe hemophilia are scant and usually describe the effects of one strategy only. Randomized controlled clinical trials comparing treatments into adulthood are not feasible and retrospective studies are likely to suffer from confounding by indication as they compare selected groups of patients(9;10).
In cases where true experiments are infeasible or impracticable, modeling techniques can be used to synthesize information from different sources. Moreover, experiments can be simulated to explore alternative strategies both for short-and long-term outcomes.
Individualized regimens provided by mixture strategies in which patients switch from one strategy to another depending on bleeding patterns are of particular interest. These individualized regimens are expected to provide the most efficient and thus most costeffective use of clotting factor concentrates.
Using data from existing cohorts, we aimed to develop a model to allow for the comparison of different treatment strategies ranging from long-term on demand therapy to different prophylactic strategies.
DESIGN AND METHODS
A model was developed in Matlab™ scripting language to simulate the life-time clinical evolution of a patient with severe hemophilia A. Knowledge on clotting factor consumption and effects of treatment for severe hemophilia from different sources was used to simulate the long-term effects of different therapeutic strategies. In order to explore all possible combinations of patient's characteristics 20,000 patients were simulated, and four treatment strategies were applied to each patient: a pure prophylactic strategy, a pure on demand strategy, and two strategies in which patients start off with prophylaxis but may switch to on demand treatment according to their bleeding pattern and age. The project was approved by the IRB of the University Medical Center Utrecht, Utrecht, the Netherlands.
TREATMENT STRATEGIES
Based on the original data, the mean dose of FVIII used for a joint bleed was 50 IU/kg for on demand treatment. A detailed description of prophylaxis according to the Dutch regimen was published elsewhere (11) . In short: prophylaxis is started after the first joint 
MODELLING PROCESS
The model simulates three main characteristics of a patient with severe hemophilia: (1) the average of the patients' annual number of joint bleeds, (2) the age at first joint bleed and (3) the patients' life expectancy. The first step in the model is to draw these three main patient characteristics. All data were drawn from actual distributions as obtained from the Dutch data (Appendix), and therefore properly reflect the heterogeneity amongst patients with hemophilia A. The median age at first joint bleed was 2.2 (95% CI: 0.29 -5.24). The median life expectancy for men was derived from the Dutch National Bureau 8 of Statistics and was estimated to be 77 years (95% CI: 51 -95). The age at first joint bleed and life expectancy are independent of treatment strategy.
The annual number of joint bleeds on prophylaxis drawn from the Dutch data is an average, and comes with its own distribution. Using this average number of annual joint bleeds for a particular patient, the model derives the actual annual number of joint bleeds for each year on prophylaxis for this patient (Appendix). For on demand treatment, only cross-sectional data was available, which contains no information on time-dependent variation in a given patient. In order to compensate for this we assumed the time-effect to be proportional to that observed among prophylaxis patients. In the data sets, the average annual number of joint bleeds of patients treated on demand (20.9/year) was 4.39 times higher than for patients treated with prophylaxis (4.76/year). The distribution of bleeds on OD treatment was modeled using prophylactic bleeding frequencies multiplied by 4.39 (Appendix).
Finally, two additional outcomes were deduced: the Pettersson score and the annual clotting factor consumption. The radiological Pettersson score reflects the degree of arthropathy (minimum score 0 for joints without signs of arthropathy, to a maximum score of 78 points) (12) . The relationship between bleeds and the Pettersson score has been reported previously: one point increase in Pettersson score per 12.6 joint bleeds on average (95% CI: 11.1 -14.7)(13).
The relationship between bleeds, treatment, and clotting factor consumption on prophylaxis was determined using the Dutch dataset. For on demand treatment, the French dataset was used (Appendix).
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For the two switching strategies, the model used either the pure prophylactic strategy or the on demand strategy for different treatment intervals.
For each simulated patient all four strategies were applied. Differences in outcomes are a direct result from differences in therapeutic approaches as all patient characteristics are equal for all treatment strategies. A simulation was performed for 20,000 patients and their bleeding histories, Pettersson scores, and cumulative clotting factor consumption were recorded and compared. An internal validity check showed good concordance of results, confirmed by a Kolmogorov-Smirnov goodness of fit test comparing simulated number of joint bleeds and the historical number of joint bleeds in the patient data sets (K-S = 0.32).
RESULTS
The estimated average cumulative number of joint bleeds, Pettersson score, and clotting factor consumption per patient according to age and therapeutic strategy are shown in Table 3 For a correct interpretation of the results, some aspects of the design of the model need to be discussed.
The validity of the model depends heavily on the data it is built upon. In this case, the estimated baseline characteristics are corroborated by published data: the estimated age at first joint bleed was in accordance with previous reports(15) and the current life expectancy for HIV negative and Hepatitis negative patients with severe hemophilia has almost reached that of the normal population (16) . Estimates of bleeding frequencies and clotting factor consumption on intermediate dose prophylaxis were based on those from hemophilia A patients from the cohort from the Van Creveldkliniek (17) . As expected, Pettersson scores at age 20 were lower in the simulated data than in the actual cohort studied in 1997. This may be attributed to an earlier start of prophylaxis in the simulated cohort. For the interpretation of the results of prophylactic treatment, it must be emphasized that these data concern an intermediate dose prophylactic regimen used in the Netherlands. Therefore the estimated effects of the pure prophylactic strategy cannot 13 directly be compared with results of higher dosed prophylactic regimens. However, higher dosed strategies may be easily incorporated into the present model.
Model parameters for the simulation of bleedings during on demand treatment could not be determined as accurately as for the prophylactic strategy. Due to the limited data on the number of joint bleeds and clotting factor consumption, it was assumed that the bleeding frequency for on demand treatment was independent of age, previous treatment and/or the presence of arthropathy. For young children around age 6 yrs, the mean number of joint bleeds on on-demand treatment has been reported at 0.6/month, which is lower than in our model (18) . For adult patients however, simulated bleeding frequencies for patients treated on demand (mean 20.9 joint bleeds per year) were in accordance with frequencies of 16.5/yr and 11.1 per six months reported in large studies by Aledort(19) and Schramm(8) respectively. The mean Pettersson score at age 23 was 26 in the model, and 19 in the Molho paper(7). Mean simulated clotting factor consumption for on demand treatment was 1330 IU/kg/yr. Reported means were 1038 (19) and 1224 IU/kg/yr respectively (8) . All estimates of bleeding rates and clotting factor consumption however, were based on data of patients with hemophilia A under age 30. As bleeding frequencies appeared constant across ages, the model based estimate is expected to be accurate. For clotting factor consumption however, we also assumed stabilization from age 30 onwards. This is in contrast with previous studies, suggesting an increase of clotting factor consumption with increasing joint damage (20) . If this is correct, clotting factor consumption after age 30 would be underestimated by the current model. Likewise, the estimated effect of joint bleeds on arthropathy was only studied for patients on prophylaxis. Modification of the effect of bleeds by age was not considered: some suggest that immature cartilage is more susceptible to damage by blood (21) Due to the lack of data for patients with hemophilia B, the present model was built for patients with hemophilia A only. Its results may not directly be applied to hemophilia B patients, as dosing of FIX is different and there is growing evidence that patients with hemophilia B have a milder bleeding phenotype (22) (23) (24) .
In this study, clotting factor consumption was used to reflect treatment intensity, which is strongly associated with direct medical costs (7;25) . By adding information on other medical costs (e.g. costs of orthopedic surgery), and benefits, the model evolve to become an economic evaluation tool. Until now, only Smith et al. (25) , Miners(26; 27) and Risebrough(28) have used modeling techniques to study the cost effectiveness of prophylactic and on demand treatment. None of these models were based on individual patient data modeling, and therefore none of these can be used to explore the clinical consequences of alternating different treatment strategies.
In order to enhance the validity of the micro-simulation model, additional data are needed. Especially longitudinal data on the natural history of bleeding episodes in patients subject to on demand treatment are lacking in the current version. Moreover, additional relevant outcome parameters could be incorporated, including health-related quality of life, quality adjusted life-years (QALY's) and labor force participation, to produce more enhanced estimates of long-term effects. By adding additional data on costs and benefits, the model could be used to perform economic evaluations.
How can we use the results from the current micro-simulation model? The model can be used to evaluate expected effects of hypothetical treatment strategies for hemophilia A.
The results of the strategies modeled here clearly show that different treatment strategies yield very different results, and suggest that individualization according to bleeding phenotype should be considered. In the case of hemophilia, where long-term clinical trials are infeasible, models help to consider the outcome of different potential treatment strategies with a life-long perspective. However, their predictive power relies entirely on their ability to accurately predict bleeding patterns.
In conclusion, the present model enables the simulation and evaluation of different treatment strategies in individual patients. It is a first step towards a tool that allows evaluation of the consequences of different treatment strategies for severe hemophilia A with a life-time perspective, and may eventually evolve into a full economic evaluation model.
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